|
|
|
|
LEADER |
04367nam a22003495i 4500 |
001 |
978-0-387-49785-3 |
005 |
20191023213106.0 |
007 |
cr nn 008mamaa |
008 |
100301s2007 xxu| s |||| 0|eng d |
020 |
|
|
|a 9780387497853
|
024 |
7 |
|
|a 10.1007/978-0-387-49785-3
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Prodrugs
|b Challenges and Rewards /
|c edited by Valentino Stella, Ronald Borchardt, Michael Hageman, Reza Oliyai, Hans Maag, Jefferson Tilley.
|
250 |
|
|
|a 1st ed. 2007.
|
260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2007.
|
300 |
|
|
|a XVIII, 1464 p.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Biotechnology: Pharmaceutical Aspects ;
|v V
|
505 |
0 |
|
|a A Case for Prodrugs -- A Case for Prodrugs -- Problems Addressable by Prodrugs -- Prodrug Approaches to Enhancing the Oral Delivery of Poorly Permeable Drugs -- Topical Delivery Using Prodrugs -- Prodrug approaches to ophthalmic drug delivery -- Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery -- Prodrugs and Parenteral Drug Delivery -- Poly (ethylene glycol) Prodrugs: Altered Pharmacokinetics and Pharmacodynamics -- Prodrugs to Reduce Presystemic Metabolism -- Controlled Release — Small Molecules -- Controlled Release - Macromolecular Prodrugs -- Controlled Release - Proenzymes -- Targeting - Theoretical and Computational Models -- Targeting - Cancer — Small Molecules -- Monoclonal Antibody Drug Conjugates for Cancer Therapy -- Antibody-Directed Enzyme Prodrug Therapy -- Prodrugs for Liver-targeted Drug Delivery -- Prodrug Approaches for Drug Delivery to the Brain -- Lymphatic Absorption of Orally Administered Prodrugs -- Colonic Delivery -- Functional Group Approach to Prodrugs -- Prodrugs of Carboxylic Acids -- Prodrugs of Alcohols and Phenols -- Prodrugs of Amines -- Prodrugs of Amides, Imides and Other NH-acidic Compounds -- Prodrugs of Benzamidines -- Prodrugs of Phosphonates, Phosphinates, and Phosphates -- Functional Group Approaches to Prodrugs: Functional Groups in Peptides -- Macromolecular Prodrugs of Small Molecules -- Miscellaneous Functional Groups -- Prodrugs — Preclinical and Clinical Considerations -- Prodrugs: Absorption, Distribution, Metabolism, Excretion (ADME) Issues -- Formulation Challenges of Prodrugs -- Safety Assessment of Prodrugs -- Toxicological Issues with Pivalate Prodrugs -- Case Studies -- Case Study: Adefovir Dipivoxil: An Oral Prodrug of Adefovir -- Case Study: Amifostine: (Ethyol®) -- Case Study: Capecitabine: A Prodrug of 5-Fluorouracil -- Case Study: Cefditoren Pivoxil: An Oral Prodrug of Cefditoren -- Case Study: Cefuroxime Axetil: An Oral Prodrug of Cefuroxime -- Case Study: Clindamycin 2-Phosphate, A Prodrug of Clindamycin -- Case Study: Enalapril: A Prodrug of Enalaprilat -- Case Study: Famciclovir: A Prodrug of Penciclovir -- Case Study: Fosamprenavir: A Prodrug of Amprenavir -- Case Study: Fosinopril -- Case Study: Fosphenytoin: A Prodrug of Phenytoin -- Case Study: Irinotecan (CPT-11), A Water-soluble Prodrug of SN-38 -- Case Study: Latanoprost: Isopropylester of a Prostaglandin F2? Analog -- Case Study: Moexipril Hydrochloride: A Prodrug of Moexiprilat -- Case Study: Mycophenolate Mofetil -- Case Study: Olmesartan Medoxomil: A Prodrug of Olmesartan -- Case Study: Omeprazole (Prilosec®) -- Case Study: Oseltamivir: An Orally Bioavailable Ester Prodrug of Oseltamivir Carboxylate -- Case Study: Parecoxib: A Prodrug of Valdecoxib -- Case Study: Tenofovir Disoproxil Fumarate: An Oral Prodrug of Tenofovir -- Case Study: Travoprost: A Potent PGF2? Analog -- Case Study: Valacyclovir: A Prodrug of Acyclovir -- Case Study: Valganciclovir: A Prodrug of Ganciclovir -- Case Study: Vantin: A Prodrug of Cefpodoxime -- Case Study: Ximelagatran: A Double Prodrug of Melagatran.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
700 |
1 |
|
|a Stella, Valentino.
|e editor.
|
700 |
1 |
|
|a Borchardt, Ronald.
|e editor.
|
700 |
1 |
|
|a Hageman, Michael.
|e editor.
|
700 |
1 |
|
|a Oliyai, Reza.
|e editor.
|
700 |
1 |
|
|a Maag, Hans.
|e editor.
|
700 |
1 |
|
|a Tilley, Jefferson.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-0-387-49785-3
|